Proteome Sciences plc
Research Proteome Sciences plc (PRM.L) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- TickerPRM.L
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyGBX
- Financial periodFY2025
- RevenueGBP 3.76M
- Revenue growth-23.1%
- Net income-GBP 3.06M
- Free cash flow-GBP 143.00K
- Gross margin-2.2%
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 3.76M | -GBP 3.06M | -GBP 143.00K | -2.2% | n/a | GBP 781.00K | GBP 15.77M | -GBP 9.53M |
| FY2024 | GBP 4.89M | -GBP 3.41M | -GBP 1.05M | 13.7% | -0.01 | GBP 1.13M | GBP 14.52M | -GBP 6.62M |
| FY2023 | GBP 5.03M | -GBP 2.44M | -GBP 718.00K | 32.8% | -0.01 | GBP 2.03M | GBP 13.48M | -GBP 3.07M |
| FY2022 | GBP 7.78M | GBP 1.33M | GBP 1.82M | 61.3% | 0 | GBP 3.99M | GBP 11.92M | -GBP 843.00K |
| FY2021 | n/a | n/a | n/a | n/a | 0 | n/a | n/a | n/a |
About Proteome Sciences plc
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor;
Related stock research
Other Healthcare stocks
Frequently asked questions
What does Proteome Sciences plc do?
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally.